ADC Therapeutics S.A.
Status: Publicly traded
Direct answer
ADC Therapeutics S.A. is publicly traded on NYSE under the ticker ADCT.
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial...
Can you invest in ADC Therapeutics S.A.?
Yes. ADC Therapeutics S.A. trades publicly on NYSE as ADCT.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for ADC Therapeutics S.A.
Detailed equity research is provided by MarketSnap.